
  
    
      
        Background_NNP
        Opioid_NNP ligands_NNS exhibit_NN a_DT variety_NN of_IN physiological_JJ
        activities_NNS and_CC have_VBP been_VBN utilized_JJ extensively_RB in_IN medicine_NN ,_,
        most_RBS prominently_RB in_IN the_DT treatment_NN of_IN pain_NN ._. However_RB ,_, at_IN
        analgesic_JJ doses_NNS ,_, opioid_NN receptor_NN agonists_NNS or_CC partial_JJ
        agonists_NNS can_MD induce_VB unwanted_JJ side_NN effects_NNS such_JJ as_IN
        ventilatory_NN depression_NN [_NN 1_CD 2_CD ]_NN and_CC the_DT development_NN of_IN
        physical_JJ tolerance_NN and_CC dependence_NN [_NN 3_CD 4_CD ]_NN ._. Thus_RB ,_, the_DT
        search_NN for_IN opioid_NN ligands_NNS which_WDT possess_VBP analgesic_JJ effect_NN
        and_CC lack_NN untoward_NN effects_NNS has_VBZ been_VBN a_DT sought_VBN after_IN goal_NN of_IN
        the_DT medical_JJ community_NN ._. The_DT overall_JJ hypothesis_NNS that_IN drives_VBZ
        the_DT present_JJ work_NN is_VBZ that_IN the_DT ideal_JJ opioid_NN analgesics_NNS that_WDT
        exhibit_NN minimal_JJ side_NN effects_NNS might_MD be_VB drugs_NNS that_WDT bind_NN to_TO
        more_JJR than_IN one_CD opioid_NN receptor_NN ,_, but_CC differentially_RB activate_VBP
        each_DT of_IN the_DT opioid_NN receptor_NN types_NNS (_( μ_NN ,_, δ_NN ,_, κ_NN )_) ._. Such_JJ drugs_NNS
        would_MD potentially_RB act_VB as_IN a_DT full_JJ agonist_NN at_IN a_DT specific_JJ
        opioid_NN receptor_NN type_NN ,_, while_IN acting_VBG as_IN partial_JJ agonists_NNS or_CC
        antagonists_NNS at_IN the_DT other_JJ receptor_NN types_NNS ._. For_IN example_NN some_DT
        investigators_NNS have_VBP suggested_VBN that_IN opioid_NN ligands_NNS with_IN
        agonism_NN at_IN μ_NN opioid_NN receptors_NNS and_CC antagonism_NN at_IN δ_NN opioid_NN
        receptors_NNS are_VBP potentially_RB useful_JJ analgesics_NNS [_NN 5_CD 6_CD 7_CD ]_NN ._. In_IN
        cases_NNS where_WRB the_DT medicinal_NN effect_NN of_IN a_DT drug_NN is_VBZ mediated_JJ
        through_IN the_DT same_JJ opioid_NN receptor_NN type_NN that_IN also_RB elicits_NNS the_DT
        side_NN effects_NNS ,_, the_DT use_NN of_IN drugs_NNS with_IN mixed_JJ activity_NN could_MD be_VB
        most_RBS beneficial_JJ [_NN 7_CD ]_NN ._. In_IN such_JJ a_DT case_NN ,_, interaction_NN with_IN
        one_CD receptor_NN could_MD reverse_VB the_DT unwanted_JJ side_NN effects_NNS
        associated_VBN with_IN activation_NN of_IN the_DT other_JJ receptor_NN ._. In_IN order_NN
        to_TO test_VB this_DT hypothesis_NNS ,_, the_DT activation_NN profiles_NNS of_IN a_DT set_NN
        of_IN non-selective_JJ opioid_NN ligands_NNS need_VBP to_TO be_VB assessed_VBN 
        in_IN vitro_NN ,_, followed_VBN by_IN 
        in_IN vivo_NN evaluation_NN of_IN analgesic_JJ and_CC
        unwanted_JJ effects_NNS ._. The_DT completed_VBN data_NN set_VBN can_MD be_VB used_VBN to_TO
        determine_VB the_DT characteristics_NNS of_IN ligands_NNS possessing_VBG
        analgesia_NN in_IN the_DT absence_NN of_IN unwanted_JJ effects_NNS ._. One_CD of_IN the_DT
        steps_NNS in_IN such_JJ an_DT approach_NN is_VBZ presented_VBN here_RB ._.
        In_IN order_NN to_TO clearly_RB understand_VB the_DT activity_NN of_IN any_DT
        ligand_NN for_IN mechanistic_JJ characterization_NN or_CC rational_JJ drug_NN
        design_NN ,_, it_PRP is_VBZ essential_JJ that_IN the_DT ligands_NNS be_VB tested_VBN in_IN a_DT
        well-defined_JJ environment_NN under_IN identical_JJ experimental_JJ
        conditions_NNS ._. Moreover_RB ,_, the_DT use_NN of_IN a_DT transfected_JJ cell_NN system_NN
        in_IN which_WDT a_DT single_JJ receptor_NN type_NN is_VBZ expressed_VBN is_VBZ critical_JJ
        for_IN these_DT types_NNS of_IN modelling_VBG ._. Such_JJ tools_NNS were_VBD not_RB available_JJ
        until_IN recently_RB when_WRB the_DT three_CD opioid_NN receptor_NN types_NNS were_VBD
        cloned_VBN ._. We_PRP have_VBP previously_RB characterized_VBN these_DT ligands_NNS in_IN
        cells_NNS expressing_VBG only_RB δ_NN opioid_NN receptor_NN [_NN 8_CD ]_NN ._. The_DT present_JJ
        study_NN was_VBD devised_VBN to_TO characterize_VB the_DT activity_NN of_IN a_DT set_NN of_IN
        opioid_NN ligands_NNS in_IN a_DT cell_NN line_NN expressing_VBG only_RB μ_NN opioid_NN
        receptors_NNS ._. The_DT ligands_NNS selected_VBN were_VBD chosen_VBN based_VBN on_IN our_PRP$
        previous_JJ data_NNS suggesting_VBG that_IN they_PRP bind_NN to_TO all_DT three_CD opioid_NN
        receptor_NN types_NNS [_NN 9_CD ]_NN ._. Previous_JJ model_NN tissue_NN data_NNS [_NN 10_CD ]_NN
        and_CC 
        in_IN vivo_NN data_NNS [_NN 11_CD ]_NN had_VBD suggested_VBN
        that_IN some_DT of_IN these_DT drugs_NNS displayed_VBD differential_NN activation_NN
        profiles_NNS at_IN each_DT of_IN the_DT opioid_NN receptor_NN types_NNS ._. Thus_RB ,_, the_DT
        present_JJ study_NN was_VBD designed_VBN to_TO achieve_VB the_DT following_JJ goals_NNS ;_:
        (_( 1_LS )_) to_TO describe_VB the_DT activation_NN profiles_NNS of_IN a_DT set_NN of_IN opioid_NN
        ligands_NNS not_RB previously_RB defined_VBN in_IN an_DT isolated_VBN cell_NN system_NN
        expressing_VBG only_RB μ_NN opioid_NN receptor_NN ,_, and_CC (_( 2_LS )_) to_TO compare_VB the_DT
        efficacies_NNS of_IN these_DT drugs_NNS to_TO the_DT known_VBN ,_, highly_RB efficacious_JJ
        μ_NN receptor_NN agonist_NN ,_, fentanyl_NN ,_, the_DT common_JJ opioid_NN analgesic_JJ
        morphine_NN and_CC to_TO the_DT endogenous_JJ opioid_NN ligand_NN
        β-endorphin_JJ ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP employed_VBN an_DT HEK_NNP cell_NN line_NN
        stably_RB expressing_VBG μ_NN opioid_NN receptors_NNS (_( HEK-μ_NNP )_) to_TO
        characterize_VB the_DT activation_NN and_CC binding_JJ profiles_NNS of_IN fifteen_NN
        opioid_NN ligands_NNS ._. These_DT cells_NNS do_VBP not_RB express_VB endogenous_JJ μ_NN
        opioid_NN receptors_NNS and_CC are_VBP easily_RB transfected_JJ ._. Furthermore_RB ,_,
        they_PRP have_VBP previously_RB been_VBN used_VBN to_TO study_VB opioid_NN receptor_NN
        activation_NN [_NN 12_CD 13_CD 14_CD 15_CD 16_CD ]_NN by_IN measuring_VBG inhibition_NN of_IN
        forskolin-stimulated_JJ cAMP_NN production_NN ._. The_DT results_NNS obtained_VBN
        from_IN this_DT study_NN can_MD serve_VB to_TO clarify_VB the_DT categorization_NN of_IN
        each_DT of_IN the_DT ligands_NNS studied_VBN as_IN an_DT agonist_NN ,_, weak_JJ /_NN partial_JJ
        agonist_NN or_CC antagonist_NN at_IN μ_NN opioid_NN receptors_NNS ._. Moreover_RB ,_,
        these_DT results_NNS demonstrate_VBP that_IN it_PRP is_VBZ crucial_JJ to_TO understand_VB
        the_DT interaction_NN of_IN each_DT drug_NN with_IN a_DT single_JJ receptor_NN type_NN at_IN
        the_DT molecular_JJ level_NN in_IN order_NN to_TO fully_RB appreciate_VB the_DT mode_NN
        of_IN action_NN of_IN the_DT drug_NN in_IN the_DT body_NN ._.
      
      
        Results_NNS
        
          Activation_NNP assays_NNS
          Our_PRP$ results_NNS clearly_RB characterize_VBP the_DT ligands_NNS studied_VBN
          as_IN agonists_NNS or_CC antagonists_NNS at_IN μ_NN opioid_NN receptors_NNS with_IN
          respect_NN to_TO inhibition_NN of_IN adenyly_RB cyclase_NN ._. Naltrexone_NNP ,_, SKF_NNP
          10047_CD and_CC WIN_NNP 44_CD ,_, 441_CD were_VBD identified_VBN as_IN antagonists_NNS ._.
          These_DT ligands_NNS exhibited_VBN little_JJ or_CC no_DT measurable_JJ
          inhibitory_NN effect_NN on_IN forskolin-stimulated_JJ cAMP_NN production_NN
          when_WRB used_VBN alone_RB and_CC were_VBD repeatedly_RB able_JJ to_TO block_VB the_DT
          inhibitory_NN effect_NN of_IN 1_CD nM_NN etorphine_NN ._. All_DT other_JJ ligands_NNS
          studied_VBN showed_VBD agonism_NN at_IN μ_NN opioid_NN receptor_NN with_IN varying_VBG
          maximal_NN effects_NNS or_CC efficacies_NNS ranging_VBG from_IN 29_CD %_NN -_: 71_CD %_NN
          (_( Table_NNP 1_LS )_) ._. The_DT rank_NN order_NN of_IN efficacy_NN of_IN the_DT ligands_NNS
          tested_VBN were_VBD fentanyl_NN =_SYM hydromorphone_NN =_SYM β-endorphin_JJ >_NN
          etorphine_NN =_SYM lofentanil_NN =_SYM butorphanol_NN =_SYM morphine_NN =_SYM
          nalbuphine_NN =_SYM nalorphine_NN >_NN cyclazocine_NN =_SYM dezocine_NN =_SYM
          metazocine_NN ≥_NN xorphanol_NN ._. The_DT IC_NNP 
          50_CD of_IN all_DT ligands_NNS studied_VBN were_VBD between_IN
          1_CD -_: 10_CD nM_NN ,_, with_IN the_DT exception_NN of_IN etorphine_NN ,_, which_WDT was_VBD the_DT
          most_RBS potent_JJ drug_NN ,_, with_IN an_DT IC_NNP 
          50_CD of_IN 0_CD ._. 3_CD nM_NN ,_, morphine_NN ,_, which_WDT was_VBD the_DT
          least_JJS potent_JJ drug_NN with_IN an_DT IC_NNP 
          50_CD of_IN 12_CD nM_NN and_CC the_DT endogenous_JJ ligand_NN
          β-endorphin_JJ with_IN IC_NNP 
          50_CD of_IN 500_CD nM_NN ._. A_DT low_JJ affinity_NN is_VBZ
          acceptable_JJ for_IN an_DT endogenous_JJ ligand_NN that_WDT is_VBZ released_VBN at_IN
          very_RB high_JJ concentrations_NNS at_IN the_DT site_NN of_IN action_NN at_IN the_DT
          synaptic_JJ cleft_NN ._. The_DT rank_NN order_NN of_IN potency_NN of_IN the_DT drugs_NNS
          studied_VBN were_VBD ;_: etorphine_NN >_NN hydromorphone_NN >_NN dezocine_NN
          >_NN xorphanol_NN =_SYM nalorphine_NN =_SYM butorphanol_NN =_SYM lofentanil_NN
          >_NN metazocine_NN >_NN nalbuphine_NN >_NN cyclazocine_NN >_NN
          fentanyl_NN >_NN morphine_NN >_NN >_NN >_NN >_NN β-endorphin_JJ ._. As_IN
          can_MD be_VB seen_VBN ,_, the_DT rank_NN order_NN of_IN efficacy_NN was_VBD not_RB related_VBN
          to_TO the_DT rank_NN order_NN of_IN potency_NN ._. In_IN fact_NN one_CD of_IN the_DT most_RBS
          potent_JJ ligands_NNS ,_, xorphanol_NN ,_, was_VBD the_DT least_JJS efficacious_JJ ._.
          Statistical_NNP analysis_NN of_IN the_DT differences_NNS between_IN the_DT
          efficacies_NNS of_IN different_JJ ligands_NNS was_VBD carried_VBN out_IN to_TO
          distinguish_VB the_DT full_JJ agonists_NNS from_IN the_DT partial_JJ agonists_NNS ._.
          Based_VBN on_IN these_DT analyses_NNS ,_, there_EX was_VBD no_DT difference_NN in_IN the_DT
          efficacy_NN of_IN butorphanol_NN ,_, etorphine_NN ,_, lofentanil_NN or_CC
          nalorphine_NN compared_VBN to_TO fentanyl_NN or_CC hydromorphone_NN (_( p_NN >_NN
          0_CD ._. 05_CD )_) ._. However_RB ,_, morphine_NN and_CC nalbuphine_NN both_DT had_VBD
          efficacies_NNS that_WDT were_VBD less_JJR than_IN fentanyl_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) ._.
          Both_DT fentanyl_NN and_CC hydromorphone_NN showed_VBD maximal_NN efficacies_NNS
          that_WDT were_VBD not_RB significantly_RB different_JJ compared_VBN to_TO that_DT of_IN
          the_DT endogenous_JJ ligand_NN β-endorphin_JJ (_( P_NN >_NN 0_CD ._. 05_CD )_) ,_, thus_RB
          categorizing_VBG them_PRP as_IN full_JJ agonists_NNS compared_VBN to_TO
          β-endorphin_JJ ._. Finally_RB the_DT four_CD weakest_JJS agonists_NNS ,_,
          cyclazocine_NN ,_, dezocine_NN ,_, metazocine_NN and_CC xorphanol_NN all_DT
          exhibited_VBN efficacies_NNS that_WDT showed_VBD statistically_RB
          significant_JJ difference_NN when_WRB compared_VBN to_TO fentanyl_NN (_( p_NN <_NN
          0_CD ._. 01_CD )_) ,_, and_CC thus_RB were_VBD categorized_VBN as_IN partial_JJ agonists_NNS ._.
          Figure_NN 1_CD represents_VBZ the_DT dose_NN response_NN curves_NNS of_IN three_CD
          agonists_NNS and_CC one_CD antagonist_NN ._. The_DT least_JJS efficacious_JJ
          (_( xorphanol_NN ,_, Fig_NNP 1_CD a_DT )_) and_CC most_RBS efficacious_JJ (_( fentanyl_NN ,_, Fig_NNP
          1_CD b_SYM )_) ligands_NNS are_VBP shown_VBN for_IN comparison_NN ._. The_DT dose_NN response_NN
          curve_NN of_IN nalbuphine_NN that_WDT was_VBD previously_RB described_VBN as_IN an_DT
          antagonist_NN at_IN μ_NN opioid_NN receptor_NN is_VBZ also_RB shown_VBN (_( Fig_NNP 1_CD c_SYM )_) in_IN
          order_NN to_TO demonstrate_VB the_DT robustness_NNS of_IN its_PRP$ agonistic_JJ
          effect_NN at_IN μ_NN opioid_NN receptor_NN ._. Finally_RB ,_, a_DT dose_NN response_NN
          curve_NN of_IN naltrexone_NN as_IN it_PRP fully_RB blocked_VBD the_DT effect_NN of_IN 1_CD
          nM_NN etorphine_NN is_VBZ shown_VBN (_( Fig_NNP 1_CD d_SYM )_) ._.
        
        
          Binding_NNP assays_NNS
          A_DT single_JJ clone_NN of_IN transfected_JJ HEK_NNP cells_NNS stably_RB
          expressing_VBG approximately_RB 3_CD pmoles_NNS of_IN μ_NN opioid_NN receptors_NNS
          per_IN mg_NN of_IN protein_NN ,_, as_IN measured_VBN by_IN [_NN 3_CD H_NNP ]_NN -_: DAMGO_NNP binding_JJ ,_,
          was_VBD propagated_JJ and_CC used_VBN as_IN a_DT model_NN for_IN characterization_NN
          of_IN the_DT binding_JJ profiles_NNS of_IN a_DT set_NN of_IN opioid_NN ligands_NNS at_IN μ_NN
          opioid_NN receptors_NNS ._. This_DT level_NN of_IN expression_NN is_VBZ not_RB
          uncommon_JJ for_IN transfected_JJ cell_NN systems_NNS [_NN 17_CD 18_CD ]_NN ,_,
          although_IN such_JJ receptor_NN expression_NN levels_NNS may_MD appear_VB
          higher_RBR than_IN reported_VBD values_NNS from_IN brain_NN tissues_NNS ._. The_DT
          measured_VBN values_NNS from_IN specific_JJ brain_NN regions_NNS are_VBP average_JJ
          estimates_NNS over_IN an_DT entire_JJ tissue_NN or_CC region_NN and_CC not_RB that_IN of_IN
          a_DT single_JJ cell_NN and_CC the_DT actual_JJ expression_NN on_IN a_DT single_JJ cell_NN
          in_IN the_DT brain_NN is_VBZ most_RBS likely_JJ much_RB higher_JJR ._. Furthermore_RB ,_,
          these_DT high_JJ levels_NNS of_IN receptor_NN expression_NN have_VBP been_VBN
          measured_VBN in_IN cell_NN lines_NNS that_WDT were_VBD established_VBN from_IN various_JJ
          neuronal_NN tissues_NNS ._. For_IN example_NN ,_, similar_JJ levels_NNS of_IN
          expression_NN have_VBP been_VBN measured_VBN for_IN neuronal_NN cells_NNS in_IN
          culture_NN (_( SH-SY_NNP 5_CD Y_NNP cells_NNS )_) [_NN 19_CD ]_NN or_CC primary_JJ cultures_NNS of_IN
          dorsal_NN root_NN ganglion_NN sensory_JJ neurons_NNS [_NN 20_CD ]_NN ._. Thus_RB ,_, the_DT
          level_NN of_IN μ_NN receptor_NN expression_NN in_IN the_DT cell_NN line_NN used_VBN in_IN
          this_DT study_NN is_VBZ comparable_JJ to_TO that_DT of_IN cells_NNS expressing_VBG the_DT
          μ_NN opioid_NN receptors_NNS in_IN various_JJ regions_NNS of_IN the_DT nervous_JJ
          system_NN ._. Competition_NN binding_JJ studies_NNS were_VBD carried_VBN out_IN for_IN
          the_DT ligands_NNS that_WDT were_VBD shown_VBN to_TO act_VB as_IN antagonists_NNS or_CC
          weak_JJ /_NN partial_JJ agonists_NNS at_IN μ_NN opioid_NN receptors_NNS to_TO confirm_VB
          that_IN these_DT agents_NNS were_VBD in_IN fact_NN capable_JJ of_IN binding_JJ to_TO μ_NN
          opioid_NN receptors_NNS with_IN high_JJ affinity_NN ._. Competition_NN binding_JJ
          studies_NNS indicated_VBD that_IN the_DT antagonists_NNS naltrexone_NN ,_, SKF_NNP
          10047_CD and_CC WIN_NNP 44_CD ,_, 441_CD had_VBD binding_JJ affinities_NNS (_( K_NNP 
          i_NNP )_) in_IN nanomolar_NN range_NN and_CC the_DT two_CD
          weakest_JJS agonists_NNS ,_, xorphanol_NN and_CC cyclazocine_NN bound_VBN the_DT
          receptor_NN with_IN the_DT highest_JJS affinities_NNS ._. The_DT rank_NN order_NN of_IN
          affinities_NNS was_VBD determined_VBN to_TO be_VB ;_: cyclazocine_NN =_SYM xorphanol_NN
          >_NN WIN_NNP 44_CD ,_, 441_CD >_NN naltrexone_NN >_NN SKF_NNP 10047_CD >_NN
          morphine_NN ._. This_DT order_NN was_VBD in_IN agreement_NN with_IN the_DT relative_JJ
          potencies_NNS of_IN these_DT drugs_NNS ,_, showing_VBG that_DT cyclazocine_NN and_CC
          xorphanol_NN had_VBD higher_JJR affinities_NNS and_CC potencies_NNS compared_VBN to_TO
          morphine_NN ,_, although_IN they_PRP were_VBD both_DT less_RBR efficacious_JJ than_IN
          morphine_NN ._.
        
      
      
        Discussion_NNP
        A_DT well-defined_JJ receptor_NN expression_NN system_NN was_VBD used_VBN to_TO
        characterize_VB the_DT activation_NN profiles_NNS of_IN a_DT set_NN of_IN opioid_NN
        ligands_NNS and_CC to_TO compare_VB the_DT efficacies_NNS and_CC potencies_NNS of_IN
        these_DT ligands_NNS at_IN μ_NN opioid_NN receptors_NNS ._. The_DT main_JJ advantage_NN of_IN
        using_VBG transfected_JJ HEK_NNP cells_NNS for_IN this_DT study_NN is_VBZ that_IN these_DT
        cells_NNS do_VBP not_RB contain_VB endogenous_JJ μ_NN opioid_NN receptors_NNS ,_, but_CC
        express_VB the_DT G_NNP proteins_NNS necessary_JJ for_IN the_DT proper_JJ coupling_NN of_IN
        the_DT transfected_JJ genes_NNS to_TO the_DT respective_JJ second_JJ messenger_NN
        systems_NNS ._. A_DT well_RB established_VBN method_NN for_IN assessing_VBG G-_NNP protein_NN
        activation_NN by_IN opioid_NN receptors_NNS and_CC characterizing_VBG activity_NN
        of_IN opioid_NN ligands_NNS is_VBZ measuring_VBG the_DT extent_NN of_IN inhibition_NN of_IN
        forskolin-stimulated_JJ adenylyl_NN cyclase_NN (_( AC_NNP )_) activity_NN [_NN 12_CD 13_CD
        14_CD 21_CD 22_CD 23_CD ]_NN ._. Adenylyl_NNP cyclase_NN has_VBZ been_VBN implicated_VBN in_IN
        playing_VBG a_DT role_NN in_IN mediating_VBG the_DT analgesic_JJ effect_NN of_IN opioid_NN
        ligands_NNS through_IN μ_NN opioid_NN receptors_NNS [_NN 24_CD 25_CD 26_CD 27_CD 28_CD ]_NN ._.
        Thus_RB ,_, characterizing_VBG the_DT ability_NN of_IN opioid_NN ligands_NNS to_TO
        inhibit_VB cAMP_NN production_NN ,_, such_JJ as_IN described_VBN in_IN this_DT report_NN ,_,
        could_MD be_VB used_VBN as_IN an_DT index_NN for_IN assessing_VBG their_PRP$ activity_NN as_IN a_DT
        correlate_VBP of_IN their_PRP$ analgesic_JJ effects_NNS ._. Moreover_RB ,_, a_DT simple_JJ
        well-defined_JJ system_NN ,_, such_JJ as_IN the_DT one_CD used_VBN in_IN this_DT study_NN ,_,
        can_MD be_VB very_RB beneficial_JJ in_IN describing_VBG the_DT mode_NN of_IN action_NN of_IN
        each_DT ligand_NN at_IN a_DT specific_JJ receptor_NN ._. However_RB ,_, it_PRP is_VBZ
        understood_VBN that_IN once_RB applied_VBN to_TO the_DT whole_JJ animal_NN 
        in_IN vivo_NN ,_, the_DT overall_JJ effect_NN of_IN the_DT
        drug_NN will_MD be_VB a_DT composite_NN of_IN the_DT effects_NNS of_IN the_DT drug_NN on_IN all_DT
        receptor_NN types_NNS interacting_VBG with_IN it_PRP ._. Furthermore_RB ,_, the_DT
        pharmacokinetic_JJ parameters_NNS ,_, such_JJ as_IN metabolism_NN ,_, tissue_NN
        absorption_NN and_CC distribution_NN of_IN the_DT drug_NN will_MD play_VB a_DT major_JJ
        role_NN in_IN the_DT overall_JJ drug_NN effect_NN 
        in_IN vivo_NN ._. 
        The_DT present_RB set_NN of_IN ligands_NNS exhibited_VBN a_DT range_NN of_IN
        efficacies_NNS and_CC potencies_NNS ._. The_DT most_RBS efficacious_JJ drug_NN was_VBD
        fentanyl_NN ,_, supporting_VBG previous_JJ 
        in_IN vivo_NN studies_NNS describing_VBG fentanyl_NN
        as_IN a_DT highly_RB potent_JJ and_CC efficacious_JJ analgesic_JJ drug_NN [_NN 11_CD ]_NN ._.
        On_IN the_DT other_JJ hand_NN xorphanol_NN was_VBD identified_VBN as_IN a_DT highly_RB
        potent_JJ ligand_NN with_IN the_DT lowest_JJS efficacy_NN in_IN inhibiting_VBG cAMP_NN
        production_NN through_IN μ_NN opioid_NN receptors_NNS ._. Clinically_NNP ,_,
        xorphanol_NN is_VBZ a_DT well_RB tolerated_JJ ,_, orally_RB active_JJ analgesic_JJ that_WDT
        provides_VBZ effective_JJ pain_NN relief_NN but_CC shows_VBZ low_JJ physical_JJ
        dependence_NN liability_NN [_NN 29_CD 30_CD ]_NN ._. It_PRP is_VBZ possible_JJ that_IN the_DT
        low_JJ physical_JJ dependence_NN liability_NN of_IN this_DT drug_NN is_VBZ due_JJ to_TO
        its_PRP$ partial_JJ agonism_NN at_IN μ_NN opioid_NN receptors_NNS ._.
        The_DT present_JJ study_NN can_MD offer_VB some_DT explanation_NN for_IN the_DT
        existing_VBG 
        in_IN vivo_NN data_NNS by_IN providing_VBG information_NN
        on_IN the_DT relative_JJ coupling_NN efficacies_NNS of_IN the_DT tested_VBN ligands_NNS
        from_IN a_DT controlled_VBN system_NN ._. For_IN example_NN ,_, one_CD study_NN
        characterizing_VBG butorphanol_NN ,_, [_NN 31_CD ]_NN described_VBD this_DT drug_NN as_IN a_DT
        mild_JJ analgesic_JJ compared_VBN to_TO morphine_NN ._. However_RB ,_, in_IN another_DT
        study_NN ,_, butorphanol_NN was_VBD reported_VBN to_TO be_VB equipotent_NN in_IN its_PRP$
        antinociceptive_JJ effect_NN to_TO that_DT of_IN morphine_NN [_NN 32_CD ]_NN ._. In_IN our_PRP$
        assays_NNS ,_, we_PRP have_VBP observed_VBN that_DT butorphanol_NN and_CC morphine_NN are_VBP
        equally_RB efficacious_JJ in_IN inhibiting_VBG cAMP_NN production_NN ,_, although_IN
        butorphanol_NN is_VBZ more_RBR potent_JJ than_IN morphine_NN in_IN this_DT assay_NN ._.
        Based_VBN on_IN these_DT two_CD sets_NNS of_IN results_NNS ,_, if_IN the_DT analgesic_JJ effect_NN
        of_IN butorphanol_NN is_VBZ mediated_JJ via_IN μ_NN opioid_NN receptors_NNS through_IN
        the_DT inhibitory_NN effect_NN of_IN these_DT receptors_NNS on_IN adenylyl_NN
        cyclase_NN ,_, the_DT equal_JJ efficacy_NN of_IN morphine_NN and_CC butorphanol_NN
        would_MD support_VB an_DT equal_JJ antinociceptive_JJ effect_NN of_IN these_DT two_CD
        drugs_NNS ._. Thus_RB ,_, such_JJ results_NNS demonstrate_VBP that_IN it_PRP is_VBZ essential_JJ
        to_TO describe_VB the_DT effect_NN of_IN ligands_NNS on_IN specific_JJ receptor_NN
        types_NNS in_IN order_NN to_TO fully_RB define_VB the_DT mode_NN of_IN action_NN of_IN each_DT
        drug_NN ._.
        Our_PRP$ data_NNS clearly_RB show_VBP that_DT nalbuphine_NN is_VBZ a_DT potent_JJ
        agonist_NN at_IN the_DT μ_NN opioid_NN receptor_NN with_IN an_DT efficacy_NN similar_JJ
        to_TO that_DT of_IN morphine_NN ,_, thus_RB agreeing_VBG with_IN 
        in_IN vivo_NN data_NNS showing_VBG that_DT morphine_NN
        and_CC nalbuphine_NN are_VBP equally_RB potent_JJ as_IN analgesics_NNS [_NN 33_CD ]_NN ._.
        However_RB ,_, other_JJ reports_NNS have_VBP described_VBN nalbuphine_NN as_RB a_DT
        "_'' mixed_JJ agonist_NN /_NN antagonist_NN "_'' with_IN agonism_NN at_IN κ_NN opioid_NN
        receptors_NNS and_CC antagonism_NN at_IN μ_NN opioid_NN receptors_NNS based_VBN on_IN 
        in_IN vivo_NN data_NNS [_NN 11_CD 33_CD ]_NN ._. This_DT
        categorization_NN is_VBZ likely_JJ due_NN to_TO the_DT fact_NN that_DT nalbuphine_NN
        has_VBZ been_VBN shown_VBN to_TO reduce_VB the_DT ventilatory_NN depressant_NN effect_NN
        of_IN other_JJ opioids_NNS ,_, while_IN adding_VBG to_TO their_PRP$ analgesic_JJ effect_NN [_NN
        33_CD ]_NN ._. Nalbuphine_NNP is_VBZ also_RB used_VBN clinically_RB to_TO reduce_VB the_DT
        opioid-mediated_JJ side_NN effects_NNS such_JJ as_IN itching_VBG ,_, without_IN
        completely_RB reversing_VBG the_DT analgesic_JJ effects_NNS of_IN the_DT full_JJ
        agonists_NNS [_NN 34_CD 35_CD 36_CD ]_NN ._. According_VBG to_TO our_PRP$ data_NNS ,_, although_IN
        nalbuphine_NN is_VBZ clearly_RB a_DT potent_JJ agonist_NN at_IN μ_NN receptors_NNS ,_, its_PRP$
        levels_NNS of_IN agonism_NN is_VBZ significantly_RB lower_JJR than_IN the_DT very_RB
        efficacious_JJ drug_NN fentanyl_NN and_CC the_DT endogenous_JJ ligand_NN
        β-endorphin_JJ ._. Therefore_RB ,_, if_IN combined_VBN with_IN a_DT drug_NN such_JJ as_IN
        fentanyl_NN ,_, or_CC in_IN the_DT presence_NN of_IN an_DT internal_JJ pool_NN of_IN
        β-endorphin_JJ ,_, nalbuphine_NN can_MD act_VB as_IN an_DT antagonist_NN in_IN
        inhibiting_VBG adenylyl_NN cyclase_NN by_IN μ_NN opioid_NN receptors_NNS ._. Thus_RB ,_,
        the_DT net_JJ effect_NN of_IN the_DT mixture_NN of_IN the_DT two_CD ligands_NNS at_IN the_DT
        level_NN of_IN the_DT whole_JJ animal_NN will_MD be_VB the_DT combined_VBN effect_NN ._. This_DT
        can_MD explain_VB the_DT usefulness_NN of_IN drugs_NNS such_JJ as_IN nalbuphine_NN in_IN
        reducing_VBG the_DT side_NN effects_NNS associated_VBN with_IN the_DT more_RBR potent_JJ
        opioid_NN analgesics_NNS while_IN not_RB totally_RB reversing_VBG the_DT analgesic_JJ
        action_NN of_IN those_DT ligands_NNS ._.
        Comparing_VBG the_DT efficacies_NNS of_IN the_DT ligands_NNS in_IN this_DT study_NN to_TO
        the_DT endogenous_JJ ligand_NN β-endorphin_JJ indicates_VBZ that_DT fentanyl_NN ,_,
        etorphine_NN ,_, lofentanil_NN ,_, butorphanol_NN and_CC hydromorphone_NN are_VBP
        all_DT full_JJ agonists_NNS ._. Thus_RB in_IN physiological_JJ pathways_NNS where_WRB
        inhibition_NN of_IN adenylyl_NN cyclase_NN mediates_NNS the_DT activity_NN of_IN μ_NN
        opioid_NN receptors_NNS ,_, these_DT drugs_NNS will_MD act_VB as_IN agonists_NNS at_IN μ_NN
        opioid_NN receptors_NNS ._. Other_JJ ligands_NNS with_IN efficacies_NNS
        significantly_RB different_JJ from_IN that_DT of_IN β-endorphin_JJ ,_, can_MD act_VB
        as_IN agonists_NNS with_IN different_JJ efficacies_NNS at_IN μ_NN opioid_NN receptors_NNS
        when_WRB administered_VBN alone_RB ._. However_RB ,_, in_IN the_DT presence_NN of_IN the_DT
        endogenous_JJ ligand_NN β-endorphin_JJ (_( when_WRB released_VBN at_IN the_DT
        synapse_NN )_) or_CC another_DT full_JJ agonist_NN ,_, a_DT weaker_JJR agonist_NN can_MD
        potentially_RB act_VB as_IN a_DT competitive_JJ antagonist_NN ._. Conversely_RB ,_, it_PRP
        is_VBZ possible_JJ for_IN ligands_NNS categorized_VBN and_CC accepted_VBN as_IN
        antagonists_NNS to_TO act_VB as_IN agonists_NNS at_IN μ_NN opioid_NN receptor_NN ,_, if_IN
        applied_VBN alone_RB at_IN high_JJ enough_JJ concentrations_NNS ,_, albeit_IN with_IN a_DT
        very_RB low_JJ efficacy_NN ._. This_DT does_VBZ not_RB mean_VB that_IN when_WRB applied_VBN to_TO
        the_DT whole_JJ organism_NN ,_, an_DT analgesic_JJ effect_NN of_IN such_JJ a_DT drug_NN will_MD
        be_VB observed_VBN ._. The_DT reason_NN is_VBZ that_IN the_DT affinity_NN ,_, efficacy_NN ,_,
        dose_NN and_CC pharmacokinetic_JJ properties_NNS of_IN the_DT drug_NN used_VBN will_MD
        influence_VB the_DT ultimate_JJ effect_NN seen_VBN in_IN the_DT organism_NN ,_, as_IN will_MD
        the_DT presence_NN of_IN other_JJ ligands_NNS in_IN the_DT system_NN ._. When_WRB drugs_NNS are_VBP
        used_VBN in_IN combination_NN ,_, the_DT net_JJ effect_NN will_MD depend_VB on_IN the_DT
        intrinsic_JJ characteristics_NNS (_( efficacy_NN and_CC affinity_NN )_) of_IN the_DT
        two_CD drugs_NNS relative_JJ to_TO each_DT other_JJ and_CC their_PRP$ relative_JJ
        concentrations_NNS at_IN the_DT site_NN of_IN action_NN ._. Consequently_RB ,_, it_PRP is_VBZ
        important_JJ to_TO have_VB a_DT clear_JJ understanding_NN of_IN the_DT
        characteristics_NNS of_IN each_DT drug_NN and_CC the_DT molecular_JJ changes_NNS that_WDT
        occur_VBP at_IN the_DT receptor_NN following_VBG receptor-drug_JJ interaction_NN [_NN
        37_CD ]_NN ._. Such_JJ knowledge_NN will_MD allow_VB one_CD to_TO target_VB a_DT specific_JJ
        receptor_NN population_NN with_IN the_DT aim_NN of_IN attaining_VBG a_DT certain_JJ
        physiological_JJ effect_NN ;_: possibly_RB by_IN mixing_VBG two_CD or_CC more_JJR drugs_NNS
        or_CC using_VBG a_DT single_JJ drug_NN that_WDT possesses_VBZ different_JJ activation_NN
        profiles_NNS at_IN various_JJ receptors_NNS ._.
      
      
        Conclusion_NNP
        In_IN summary_NN ,_, this_DT is_VBZ the_DT first_JJ detailed_JJ comparative_JJ
        report_NN of_IN the_DT inhibitory_NN effect_NN of_IN a_DT set_NN of_IN opioid_NN ligands_NNS
        on_IN the_DT accumulation_NN of_IN cAMP_NN in_IN intact_JJ cells_NNS expressing_VBG μ_NN
        opioid_NN receptors_NNS ._. The_DT activation_NN profiles_NNS of_IN these_DT ligands_NNS
        have_VBP been_VBN compared_VBN to_TO that_DT of_IN the_DT endogenous_JJ opioid_NN ligand_NN ,_,
        β-endorphin_JJ ,_, and_CC the_DT commonly_RB used_VBN opioid_NN analgesics_NNS ,_,
        morphine_NN and_CC fentanyl_NN ._. Moreover_RB ,_, this_DT report_NN serves_VBZ to_TO
        clarify_VB the_DT activation_NN profiles_NNS of_IN many_JJ previously_RB
        uncharacterised_JJ ligands_NNS in_IN cells_NNS expressing_VBG only_RB μ_NN opioid_NN
        receptors_NNS ,_, thus_RB leading_VBG to_TO a_DT better_JJR understanding_NN of_IN the_DT
        mechanism_NN of_IN action_NN of_IN these_DT drugs_NNS ._.
      
      
        Method_NNP
        
          Cell_NNP culture_NN
          Human_NNP Embryonic_NNP Kidney_NNP (_( HEK_NNP )_) 293_CD cells_NNS were_VBD maintained_VBN
          in_IN D-MEM_NNP /_NN F-_NNP 12_CD (_( Dulbecco_NNP 's_POS Modified_NNP Eagle_NNP 's_POS Medium_NNP :_:
          Nutrient_NNP Mixture_NNP F-_NNP 12_CD 1_CD :_: 1_CD mixture_NN )_) ,_, supplemented_JJ with_IN 10_CD %_NN
          (_( v_NN /_NN v_NN )_) fetal_JJ calf_NN serum_NN (_( FCS_NNP )_) ,_, 200_CD μg_NN /_NN ml_NN G-_NNP 418_CD (_( Geneticin_NNP
          ®_NN )_) in_IN a_DT humidified_JJ incubator_NN with_IN 5_CD %_NN CO_NNP 
          2_CD and_CC 95_CD %_NN air_NN ,_, at_IN 37_CD °_NN C_NNP ._. The_DT incubation_NN
          medium_NN was_VBD changed_VBN every_DT 3_CD -_: 4_CD days_NNS ._. Once_RB a_DT week_NN ,_, cells_NNS
          were_VBD re-plated_JJ at_IN 20_CD %_NN density_NN into_IN 75_CD cm_NN 2_CD tissue_NN culture_NN
          flasks_NNS ._.
        
        
          Establishing_VBG stable_JJ cells_NNS expressing_VBG μ_NN opioid_NN
          receptors_NNS
          Stably_NNP transfected_JJ HEK_NNP cells_NNS were_VBD developed_VBN as_IN
          described_VBN previously_RB [_NN 12_CD ]_NN ._. HEK_NNP 293_CD cells_NNS were_VBD
          transfected_JJ with_IN mouse_NN μ_NN opioid_NN receptor_NN cDNA_NN in_IN the_DT
          pcDNA_NN 3_CD vector_NN (_( a_DT generous_JJ gift_NN from_IN Drs_NNP ._. Chris_NNP Evans_NNP and_CC
          Duane_NNP Keith_NNP ,_, UCLA_NNP )_) using_VBG the_DT lipofectin_NN ®_NN reagent_NN (_( Life_NNP
          Technologies_NNPS ,_, Rockville_NNP ,_, MD_NNP )_) ._. One_CD clone_NN with_IN a_DT B_NNP 
          max_NN of_IN 3326_CD ±_NN 674_CD fmoles_NNS /_NN mg_NN of_IN protein_NN
          as_IN assessed_VBN by_IN [_NN 3_CD H_NNP ]_NN -_: DAMGO_NNP binding_JJ was_VBD propagated_JJ for_IN use_NN
          in_IN this_DT study_NN ._.
        
        
          Binding_NNP assays_NNS
          Saturation_NNP binding_JJ assays_NNS were_VBD carried_VBN out_IN for_IN [_NN
          3_CD H_NNP ]_NN -_: DAMGO_NNP in_IN HEK_NNP cells_NNS as_IN described_VBN previously_RB [_NN 38_CD ]_NN ._.
          Each_DT assay_NN was_VBD carried_VBN out_IN in_IN triplicates_NNS in_IN a_DT 250_CD μl_NN
          total_JJ reaction_NN volume_NN containing_VBG 20_CD -_: 25_CD μg_NN of_IN crude_NN cell_NN
          homogenate_NN per_IN assay_NN tube_NN ._. Incubation_NNP was_VBD in_IN 50_CD mM_NN Tris_NNP
          HCl_NNP buffer_NN ,_, pH_NN 7_CD ._. 4_CD at_IN room_NN temperature_NN for_IN 2_CD hours_NNS ._. The_DT
          assay_NN was_VBD terminated_VBN by_IN rapid_JJ filtration_NN through_IN Whatman_NNP
          GF_NNP /_NN B_NNP filters_NNS followed_VBN by_IN three_CD washes_NNS ,_, with_IN ice-cold_JJ
          buffer_NN ._. Radioactivity_NNP retained_VBD on_IN the_DT filters_NNS was_VBD
          measured_VBN using_VBG liquid_JJ scintillation_NN counting_NN ._.
          Competition_NN binding_JJ assays_NNS were_VBD carried_VBN out_IN in_IN crude_NN
          homogenate_NN of_IN HEK-μ_NNP cells_NNS ._. Binding_NNP was_VBD carried_VBN out_IN in_IN 250_CD
          μl_NN volume_NN of_IN 50_CD mM_NN Tris_NNP HCl_NNP buffer_NN ,_, pH_NN 7_CD ._. 4_CD in_IN the_DT
          presence_NN of_IN about_IN 0_CD ._. 5_CD -_: 1_CD nM_NN [_NN 3_CD H_NNP ]_NN -_: DAMGO_NNP and_CC increasing_VBG
          concentrations_NNS (_( 24_CD -_: 32_CD )_) of_IN unlabeled_JJ ligand_NN ._. Incubation_NNP
          and_CC washing_VBG were_VBD as_IN described_VBN above_IN ._. Binding_NNP data_NNS were_VBD
          analyzed_VBN using_VBG the_DT Affinity_NNP Analysis_NNP Software_NNP as_IN
          described_VBN before_IN [_NN 38_CD ]_NN ._. For_IN preparation_NN of_IN crude_NN cell_NN
          homogenate_NN ,_, confluent_NN cultures_NNS of_IN HEK-μ_NNP cells_NNS were_VBD
          harvested_VBN using_VBG phosphate_NN buffered_JJ saline_NN ._. Following_VBG
          centrifugation_NN ,_, the_DT cell_NN pellet_NN was_VBD resuspended_JJ in_IN
          ice-cold_JJ 50_CD mM_NN Tris_NNP HCl_NNP buffer_NN pH_NN 7_CD ._. 4_CD at_IN about_IN 10_CD
          7_CD cell_NN /_NN ml_NN ,_, and_CC homogenized_JJ using_VBG a_DT polytron_NN at_IN setting_VBG 6_CD
          for_IN 10_CD seconds_NNS ._. The_DT cell_NN homogenate_NN was_VBD stored_VBN in_IN
          aliquots_NNS at_IN -_: 86_CD °_NN C_NNP until_IN use_NN ._. Protein_NNP content_NN of_IN the_DT cell_NN
          homogenate_NN was_VBD determined_VBN using_VBG Bio-_NNP Rad_NNP protein_NN assay_NN
          reagent_NN (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) ._.
        
        
          Whole_JJ cell_NN adenylyl_NN cyclase_NN assays_NNS
          Exponentially_NNP growing_VBG HEK-μ_NNP cells_NNS were_VBD harvested_VBN and_CC
          resuspended_JJ in_IN serum_NN free_JJ DMEM_NNP /_NN F_NN 12_CD medium_NN ._. Cells_NNP were_VBD
          plated_JJ in_IN 96_CD well_RB micro_JJ titer_NN plates_NNS at_IN 5_CD ×_NN 10_CD
          4_CD cells_NNS /_NN well_RB ._. To_TO each_DT well_RB ,_, phosphodiesterase_NN inhibitor_NN
          3_CD -_: isobutyl-_NN 1_CD -_: methylxanthine_NN (_( IBMX_NNP )_) was_VBD added_VBN to_TO a_DT final_JJ
          concentration_NN of_IN 100_CD μM_NN ,_, followed_VBN by_IN addition_NN of_IN agonists_NNS
          at_IN different_JJ concentrations_NNS and_CC incubation_NN at_IN 37_CD °_NN C_NNP ._.
          Following_VBG incubation_NN for_IN 15_CD minutes_NNS ,_, forskolin_NN was_VBD added_VBN
          to_TO each_DT well_RB to_TO a_DT final_JJ concentration_NN of_IN 5_CD μM_NN followed_VBN by_IN
          another_DT incubation_NN for_IN 15_CD minutes_NNS at_IN 37_CD °_NN C_NNP ._. The_DT reaction_NN
          was_VBD terminated_VBN by_IN aspiration_NN of_IN the_DT medium_NN and_CC addition_NN
          of_IN lysis_NNS buffer_NN from_IN the_DT Biotrak_NNP ™_NN cAMP_NN Enzyme_NNP Immunoassay_NNP
          kit_NN from_IN Amersham_NNP Pharmacia_NNP Biotech_NNP (_( Buckinghamshire_NNP ,_,
          England_NNP )_) ._. The_DT rest_NN of_IN the_DT assay_NN followed_VBD the_DT protocol_NN
          provided_VBN with_IN the_DT kit_NN ._. Actual_JJ amount_NN of_IN cAMP_NN was_VBD
          determined_VBN for_IN each_DT sample_NN in_IN comparison_NN to_TO a_DT standard_JJ
          curve_NN of_IN known_VBN amounts_NNS of_IN cAMP_NN provided_VBN in_IN the_DT cAMP_NN kit_NN ,_,
          as_IN described_VBN in_IN the_DT kit_NN protocol_NN ._.
        
        
          Agonism_NNP
          Agonistic_NNP activity_NN of_IN opioid_NN ligands_NNS was_VBD assessed_VBN by_IN
          measuring_VBG the_DT inhibitory_NN effect_NN of_IN the_DT drugs_NNS on_IN
          forskolin-stimulated_JJ cAMP_NN accumulation_NN ._. Data_NNP were_VBD
          normalized_JJ to_TO the_DT top_NN of_IN the_DT curve_NN (_( no_DT drug_NN ,_, 100_CD %_NN )_) ,_,
          expressed_VBD as_IN percent_NN inhibition_NN of_IN forskolin-stimulated_JJ
          cAMP_NN accumulation_NN and_CC were_VBD fitted_JJ to_TO a_DT sigmoidal_NN function_NN
          by_IN using_VBG one_CD site_NN competition_NN function_NN as_IN described_VBN
          below_IN ._. The_DT efficacy_NN of_IN each_DT ligand_NN was_VBD defined_VBN as_IN percent_NN
          inhibition_NN of_IN forskolin-stimulated_JJ cAMP_NN production_NN
          compared_VBN to_TO no_DT drug_NN levels_NNS (_( 0_CD %_NN inhibition_NN ,_, 100_CD %_NN cAMP_NN
          production_NN )_) ._.
        
        
          Antagonism_NNP
          Compounds_NNP with_IN no_DT or_CC very_RB small_JJ 
          in_IN vitro_NN agonistic_JJ activity_NN
          (_( <_NN 20_CD %_NN inhibition_NN of_IN cAMP_NN production_NN )_) for_IN which_WDT the_DT
          dose_NN response_NN curves_NNS could_MD not_RB be_VB fitted_JJ due_NN to_TO the_DT small_JJ
          effect_NN ,_, were_VBD tested_VBN for_IN antagonism_NN ._. Antagonists_NNP were_VBD
          defined_VBN as_IN ligands_NNS that_WDT were_VBD able_JJ to_TO repeatedly_RB block_VB the_DT
          inhibitory_NN effect_NN of_IN 1_CD nM_NN etorphine_NN on_IN
          forskolin-stimulated_JJ cAMP_NN production_NN ._. Antagonist_NNP was_VBD
          added_VBN to_TO the_DT cells_NNS along_IN with_IN IBMX_NNP ._. After_IN 15_CD minutes_NNS of_IN
          incubation_NN ,_, the_DT agonist_NN was_VBD added_VBN and_CC the_DT cells_NNS were_VBD
          incubated_JJ with_IN both_DT drugs_NNS for_IN an_DT additional_JJ 10_CD minutes_NNS ._.
          The_DT rest_NN of_IN the_DT assay_NN was_VBD as_IN described_VBN above_IN ._.
        
        
          Curve_NNP fitting_JJ
          The_DT analysis_NN of_IN drug_NN activity_NN was_VBD performed_VBN using_VBG
          PRISM_NNP software_NN (_( GraphPad_NNP Software_NNP ,_, Inc_NNP ._. San_NNP Diego_NNP ,_, CA_NNP )_) ._. A_DT
          computer-generated_JJ "_'' best_JJS fit_VB "_'' of_IN non-linear_JJ regression_NN
          data_NNS was_VBD used_VBN to_TO provide_VB an_DT estimate_NN of_IN the_DT inhibitory_NN
          concentration_NN at_IN 50_CD %_NN (_( IC_NNP 
          50_CD )_) ._. Dose_NNP response_NN data_NNS generated_VBN by_IN
          cAMP_NN enzyme_NN immunoassay_NN (_( EIA_NNP )_) system_NN were_VBD fitted_JJ to_TO the_DT
          one_CD site_NN competition_NN function_NN ._.
        
        
          Data_NNP processing_NN
          Data_NNS from_IN each_DT dose_NN response_NN curve_NN were_VBD normalized_JJ to_TO
          the_DT top_NN of_IN the_DT respective_JJ curve_NN ._. The_DT normalized_JJ data_NN from_IN
          multiple_JJ dose_NN response_NN curves_NNS were_VBD combined_VBN and_CC a_DT new_JJ
          dose_NN response_NN curve_NN was_VBD fitted_JJ to_TO the_DT combined_VBN data_NN and_CC
          the_DT IC_NNP 
          50_CD and_CC maximal_NN inhibition_NN were_VBD
          determined_VBN for_IN the_DT combined_VBN data_NN ._.
        
        
          Drugs_NNS
          Forskolin_NNP ,_, fentanyl_NN ,_, IBMX_NNP ,_, hydromorphone_NN ,_, and_CC
          naltrexone_NN were_VBD obtained_VBN from_IN Sigma-_NNP Aldrich_NNP (_( St_NNP ._. Louis_NNP ,_,
          MO_NNP )_) ,_, nalbuphine_NN and_CC β-endorphin_JJ were_VBD obtained_VBN from_IN RBI_NNP
          (_( Natik_NNP ,_, MA_NNP )_) ,_, cyclazocine_NN ,_, etorphine_NN ,_, metazocine_NN ,_,
          morphine_NN ,_, nalorphine_NN ,_, and_CC SKF_NNP 10047_CD were_VBD obtained_VBN from_IN
          National_NNP Institute_NNP of_IN Drug_NNP Abuse_NNP (_( Bethesda_NNP ,_, MD_NNP )_) ,_,
          lofentanil_NN was_VBD from_IN Janssen_NNP Pharmaceutical_NNP Inc_NNP ._.
          (_( Titusville_NNP ,_, NJ_NNP )_) ,_, Dezocine_NNP was_VBD from_IN Wyeth_NNP Laboratories_NNPS
          (_( Philadelphia_NNP ,_, PA_NNP )_) ,_, Win_NNP 444_CD ,_, 441_CD was_VBD from_IN Sterling_NNP
          Winthrop_NNP Pharmaceutical_NNP and_CC Xorphanol_NNP was_VBD from_IN Miles_NNP Inc_NNP ._.
          Pharmaceutical_NNP Division_NNP (_( West_NNP Haven_NNP ,_, CT_NNP )_) ._. All_DT tissue_NN
          culture_NN reagents_NNS were_VBD purchased_VBN from_IN Life_NNP Technologies_NNPS
          (_( Rockville_NNP ,_, MD_NNP )_) ._. DAMGO_NNP was_VBD obtained_VBN from_IN Peninsula_NNP
          Laboratories_NNPS (_( San_NNP Carlos_NNP ,_, CA_NNP )_) ,_, and_CC [_NN 3_CD H_NNP ]_NN -_: DAMGO_NNP was_VBD from_IN
          Multiple_NNP Peptide_NNP Systems_NNPS (_( San_NNP Diego_NNP ,_, CA_NNP )_) ._. All_DT other_JJ
          reagents_NNS were_VBD of_IN analytical_JJ grade_NN from_IN standard_JJ
          commercial_JJ sources_NNS ._. All_DT ligands_NNS used_VBN were_VBD prepared_VBN as_IN 10_CD
          mM_NN stock_NN solutions_NNS in_IN water_NN except_IN WIN_NNP 44_CD ,_, 441_CD ,_, which_WDT was_VBD
          5_CD mM_NN ._. All_DT ligands_NNS were_VBD dissolved_VBN in_IN distilled_VBN water_NN
          except_IN cyclazocine_NN ,_, dezocine_NN ,_, etorphine_NN ,_, which_WDT were_VBD
          dissolved_VBN in_IN 100_CD %_NN ethanol_NN ._. For_IN the_DT drugs_NNS dissolved_VBN in_IN
          ethanol_NN ,_, the_DT final_JJ concentration_NN of_IN ethanol_NN was_VBD <_NN 0_CD ._. 01_CD %_NN
          which_WDT had_VBD no_DT affect_NN on_IN the_DT assays_NNS performed_VBN ._.
        
        
          Statistical_NNP Analysis_NNP
          Maximal_NNP inhibitory_NN effect_NN of_IN each_DT ligand_NN was_VBD compared_VBN
          to_TO the_DT levels_NNS of_IN maximal_NN inhibition_NN by_IN β-endorphin_JJ ,_,
          fentanyl_NN ,_, morphine_NN and_CC xorphanol_NN using_VBG ANOVA_NNP analysis_NN
          with_IN Dunnett_NNP 's_POS multiple_JJ comparison_NN as_IN post-test_JJ using_VBG
          PRISM_NNP software_NN (_( GraphPad_NNP Software_NNP ,_, Inc_NNP ._. San_NNP Diego_NNP ,_, CA_NNP )_) ._.
          Significant_JJ difference_NN between_IN the_DT inhibitory_NN effects_NNS of_IN
          two_CD ligands_NNS was_VBD determined_VBN whenever_WRB p_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        PG_NNP carried_VBD out_RP some_DT of_IN the_DT cAMP_NN assays_NNS ,_, performed_VBN data_NNS
        and_CC statistical_JJ analysis_NN and_CC drafted_VBD the_DT manuscript_NN ._. HD_NNP
        carried_VBD out_RP a_DT large_JJ portion_NN of_IN the_DT cAMP_NN assays_NNS and_CC data_NNS
        analysis_NN work_NN ._. The_DT contributions_NNS of_IN the_DT first_JJ two_CD authors_NNS
        were_VBD equal_JJ to_TO the_DT overall_JJ goals_NNS of_IN the_DT study_NN ._. JDC_NNP provided_VBD
        intellectual_JJ input_NN and_CC critical_JJ interpretation_NN of_IN the_DT data_NNS ._.
        JL_NNP conceived_VBD of_IN the_DT study_NN ,_, participated_VBD in_IN its_PRP$ design_NN and_CC
        coordination_NN ,_, carried_VBD out_RP the_DT binding_JJ assays_NNS and_CC finalized_VBD
        the_DT manuscript_NN for_IN publication_NN ._.
      
    
  
